Loading people...
Christiana Bardon is the Co-Managing Partner at MPM BioImpact in Boston, Massachusetts, where she leads the firm's oncology equities strategy as a portfolio manager. Before assuming her current position, she worked as a health care analyst at Fidelity Investments covering biotechnology and diagnostics, and served as a general partner at Burrill & Company. In 2021, she co-led the closing of the $850 million Oncology Impact Fund 2, which was the largest dedicated crossover fund in oncology at the time, and subsequently raised the BioVentures Fund during the market contraction in 2022. She currently serves on the board of directors for several biotechnology companies, including ElevateBio, Orna Therapeutics, and Reunion Neuroscience. Holding an MD from Harvard Medical School and science degrees from MIT, Bardon focuses her investment strategy on transformative therapeutics and public market healthcare equities.
Christiana Bardon stands as a prominent figure in the biotechnology venture capital landscape, serving as a Managing Partner at MPM Capital. MPM Capital is renowned for its pioneering approach to investing in and building companies dedicated to developing transformative therapies for serious diseases. As a key leader within the firm, Dr. Bardon plays a crucial role in identifying and nurturing the next generation of life science innovations.
A significant aspect of her leadership at MPM Capital includes co-founding and co-managing the Oncology Impact Fund (OIF). This specialized fund is dedicated to investing in companies that are at the forefront of cancer research and treatment, aiming to accelerate the development of novel oncology therapies. Beyond oncology, Dr. Bardon's investment focus extends to other high-impact therapeutic areas, including rare diseases and conditions with significant unmet medical needs. She is deeply committed to supporting companies that leverage cutting-edge science to address critical health challenges and deliver meaningful patient outcomes.
Dr. Bardon's distinguished career background provides her with a unique perspective that blends deep scientific understanding with astute financial acumen. She holds an M.D. from Harvard Medical School and an M.B.A. from Harvard Business School, a powerful combination that underpins her ability to evaluate complex scientific propositions through a rigorous business lens. Prior to her tenure at MPM Capital, Dr. Bardon honed her expertise as a healthcare analyst and portfolio manager at several leading investment firms, including Fidelity, SG Cowen, and Leerink Swann. This extensive experience in both public and private equity markets within the life sciences sector has equipped her with a comprehensive understanding of the entire drug development lifecycle and market dynamics.
Her investment strategy at MPM Capital is characterized by a commitment to fostering groundbreaking science. She actively seeks out companies with robust scientific platforms, innovative drug discovery approaches, and strong management teams capable of executing ambitious development plans. Whether through company creation, where MPM helps build new ventures from inception, or by investing in promising early-stage and growth-stage companies, Dr. Bardon is instrumental in guiding these enterprises toward clinical and commercial success. Her work directly contributes to advancing therapeutic development across various modalities, from small molecules and biologics to gene therapies, always with an eye toward therapies that can truly make a difference in patients' lives.
Through her leadership at MPM Capital and her strategic investments, Christiana Bardon continues to be a driving force in healthcare innovation. Her dedication to translating scientific breakthroughs into tangible medical solutions underscores her mission to improve global health outcomes, particularly in areas like oncology where the need for new treatments remains urgent. Her contributions are vital in shaping the future of biotechnology and bringing hope to patients worldwide.
Christiana Bardon is a Managing Partner at MPM Capital, a leading biotechnology venture capital firm. She is known for co-founding and co-managing the Oncology Impact Fund and investing in innovative life science companies.
Christiana Bardon primarily invests in groundbreaking life science companies focused on developing therapies for serious diseases. Her key investment areas include oncology, rare diseases, and other therapeutic fields with significant unmet medical needs.
Christiana Bardon works as a Managing Partner at MPM Capital, a prominent biotechnology venture capital firm.
